Clinical trial NCT05210634: Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants
Official title: A Two-Phase, Randomized, Double-Blind, PlaceboControlled Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Adults
Lead sponsor: Canopy Growth Corporation
Sponsor class: INDUSTRY
First posted: 2022-01-27
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: The is a two-phase, within participant crossover study.
Primary purpose: OTHER

Brief summary: This is a two-phase, randomized, double-blind, placebo-controlled, within-participant crossover study to assess the safety, tolerability, PK, and PD of five oral doses of CHI-915 versus placebo in healthy adult participants ages 18-55 years.


Eligibility criteria: Inclusion Criteria:

1. Is a healthy adult aged 18-55 years (inclusive) at the time of screening.
2. Has a body mass index between 18 and 30 kg/m2.
3. Is judged by the Investigator to be in generally good health at screening based on the results of a medical history, physical examination, 12-lead ECG, and clinical laboratory test results. Laboratory results outside of the reference range deemed to be acceptable will be documented as not clinically significant at the discretion of the Investigator.
4. For women of childbearing potential, has a negative serum pregnancy test (β-human chorionic gonadotropin \[hCG\]) at the Screening Visit and a negative urine pregnancy test at intake to the research facility.
5. Must be adequately informed of the nature and risks of the study and give written informed consent prior to screening.
6. Is, in the Investigator's opinion, reliable, able, and willing to comply with all protocol requirements and procedures (including scheduled visits).

Exclusion Criteria:

1. Women who are pregnant, lactating, breastfeeding, or planning a pregnancy.
2. Women of childbearing potential, or men who are sexually active with a woman of childbearing potential, who are unwilling or unable to use an acceptable method of contraception (abstinence or the use of a highly effective method of contraception, including hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, vasectomy, or intrauterine device) from at least 21 days prior to the first dose of study medication until 28 days after the last dose of study medication. Participants with same sex partners or who maintain abstinence do not require contraception.
3. Person has history of diagnosis related to hepatic function and/or significantly impaired hepatic function (alanine aminotransferase \[ALT\] \>3x upper limit of normal \[ULN\] or total bilirubin \[TBL\] \>2 x ULN) OR the ALT or aspartate aminotransferase (AST) \>2 x ULN and TBL \>2 x ULN (or international normalized ratio \[INR\] \>1.5).
4. Has a history of epilepsy.
5. Has used tobacco/nicotine-containing products on more than 10 occasions within 30 days of dosing with study IP or during the study.
6. Has used any prescription drugs or herbal supplements (except hormonal contraception) within 30 days prior to receiving the first dose of IP, unless approved by the Investigator and stable for at least 30 days prior to the first dose of IP through the final study visit.
7. Use of any over-the-counter drugs, vitamins, or supplements within 24 hours prior to dosing with the IP.
8. Has or has previously had a positive result for the presence of Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibodies (HCVAb), or human immunodeficiency virus (HIV) antibodies.
9. Has a positive breath, urine, or serum test for ethanol or a positive urine screen for cocaine, THC, barbiturates, amphetamines, methamphetamines, benzodiazepines, methylenedioxymethamphetamine, phencyclidine, methadone, or opiates at the Screening Visit or prior to IP administration.
10. Any clinically significant condition or abnormal finding at the Screening Visit that would, in the opinion of the Investigator, preclude study participation or interfere with evaluation of the IP.
11. Has a history of a known significant allergic condition, significant drug-related hypersensitivity, or allergic reaction to any compound or chemical class related to cannabis, including phytocannabinoids and cannabinoid analogues, or excipients utilized within the IP.
12. Has taken grapefruit products and/or Seville oranges within the 7 days prior to dosing with study medication or during the study.
13. Is taking a prohibited medication or supplement including warfarin, clobazam, valproic acid, phenobarbital, mTOR inhibitors, oral tacrolimus, and St. John's Wort within 30 days prior to receiving the first dose of IP or during the study.
14. Has used cannabis, synthetic cannabinoid, or cannabinoid analogues (e.g., dronabinol, nabilone), hemp products, synthetic cannabinoid receptor agonists (e.g., spice, K2), or any cannabidiol (CBD) or THC-containing product (e.g., Sativex, Epidiolex) within 4 weeks of the Screening Visit or during the study and has used cannabis on more than 25 occasions in the last 12 months.
15. Meets criteria for past-year Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)-defined psychiatric disorder, or moderate to severe substance use disorder.
16. Has a lifetime history of psychosis or schizophrenia or a first-degree relative experiencing psychosis or schizophrenia.
17. Endorses current suicidal intent as indexed by endorsement of questions #4 or #5 on the Columbia-Suicide Severity Rating Scale (C-SSRS).
18. Has suspected or confirmed cardiovascular disease.
19. Has participated in any investigational product or device study within 30 days prior to receiving the first dose of IP or is scheduled to participate in another investigational product or device study during the course of this study.
20. Demonstrates behavior indicating unreliability or inability to comply with the requirements of the protocol.

Primary outcomes:
measure: Incidence, type and severity of AEs/SAEs
timeFrame: Day 1
measure: Incidence, type and severity of AEs/SAEs
timeFrame: Day 8
measure: Incidence, type and severity of AEs/SAEs
timeFrame: Day 15
measure: Incidence, type and severity of AEs/SAEs
timeFrame: Day 22
measure: Incidence, type and severity of AEs/SAEs
timeFrame: Day 29
measure: Incidence, type and severity of AEs/SAEs
timeFrame: Day 36
measure: Change in blood pressure
timeFrame: Day 1
measure: Change in heart rate
timeFrame: Day 1
measure: Change in respiratory rate
timeFrame: Day 1
measure: Change in body temperature
timeFrame: Day 1
measure: Change in blood pressure
timeFrame: Day 8
measure: Change in heart rate
timeFrame: Day 8
measure: Change in respiratory rate
timeFrame: Day 8
measure: Change in body temperature
timeFrame: Day 8
measure: Change in blood pressure
timeFrame: Day 15
measure: Change in respiratory rate
timeFrame: Day 15
measure: Change in heart rate
timeFrame: Day 15
measure: Change in body temperature
timeFrame: Day 15
measure: Change in blood pressure
timeFrame: Day 22
measure: Change in respiratory rate
timeFrame: Day 22
measure: Change in heart rate
timeFrame: Day 22
measure: Change in body temperature
timeFrame: Day 22
measure: Change in blood pressure
timeFrame: Day 29
measure: Change in heart rate
timeFrame: Day 29
measure: Change in respiratory rate
timeFrame: Day 29
measure: Change in body temperature
timeFrame: Day 29
measure: Change in blood pressure
timeFrame: Day 36
measure: Change in heart rate
timeFrame: Day 36
measure: Change in respiratory rate
timeFrame: Day 36
measure: Change in body temperature
timeFrame: Day 36
measure: Change in ECG results
timeFrame: Day 1
measure: Change in ECG results
timeFrame: Day 8
measure: Change in ECG results
timeFrame: Day 15
measure: Change in ECG results
timeFrame: Day 22
measure: Change in ECG results
timeFrame: Day 29
measure: Change in ECG results
timeFrame: Day 36
Secondary outcomes:
measure: Maximum effect for the item "energetic" on the DEQ
timeFrame: Day 1
measure: Maximum effect for the item "energetic" on the DEQ
timeFrame: Day 8
measure: Maximum effect for the item "energetic" on the DEQ
timeFrame: Day 15
measure: Maximum effect for the item "energetic" on the DEQ
timeFrame: Day 22
measure: Maximum effect for the item "energetic" on the DEQ
timeFrame: Day 29
measure: Maximum effect for the item "energetic" on the DEQ
timeFrame: Day 36
measure: Sustained attention - maximum total time on the DVT
timeFrame: Day 1
measure: Sustained attention - maximum total time on the DVT
timeFrame: Day 8
measure: Sustained attention - maximum total time on the DVT
timeFrame: Day 15
measure: Sustained attention - maximum total time on the DVT
timeFrame: Day 22
measure: Sustained attention - maximum total time on the DVT
timeFrame: Day 29
measure: Sustained attention - maximum total time on the DVT
timeFrame: Day 36
measure: Pharmacokinetic profile of THCv
timeFrame: Day 1
measure: Pharmacokinetic profile of THCv
timeFrame: Day 8
measure: Pharmacokinetic profile of THCv
timeFrame: Day 15
measure: Pharmacokinetic profile of THCv
timeFrame: Day 22
measure: Pharmacokinetic profile of THCv
timeFrame: Day 29
measure: Pharmacokinetic profile of THCv
timeFrame: Day 36
measure: Pharmacokinetic profile of THCv
timeFrame: Day 1
measure: Pharmacokinetic profile of THCv
timeFrame: Day 8
measure: Pharmacokinetic profile of THCv
timeFrame: Day 15
measure: Pharmacokinetic profile of THCv
timeFrame: Day 22
measure: Pharmacokinetic profile of THCv
timeFrame: Day 29
measure: Pharmacokinetic profile of THCv
timeFrame: Day 36
Other outcomes:
Locations:
city: Saint Paul
country: United States
facility: Nucleus Network
state: Minnesota
Study officials:
References: